


Supplemental Digital Content 3: Study Design and Treatment Schedule (Randomized set*)



*Consisted of all randomized patients.

†vPDT, ranibizumab, or both were administered at month 3 and at all following monthly visits at the investigator's discretion.

BL, baseline; R, randomization; VA, visual acuity; vPDT, verteporfin photodynamic therapy